梯瓦制药 TEVA
$42.61 +$0.83 (+1.99%)
休市 · Nov 6, 8:20 pm ET · 最新盘后价 $42.75 +0.33%
开盘$41.47
昨收$41.78
当日区间$41.41 – $42.63
成交量6.20M
市值$49.72B
市盈率（TTM）99.1
股息率–
TEVA 相关新闻
匹配 Teva Pharmaceutical Industries 或代码 TEVA 的头条新闻，按最新排序。
- Leerink Partners Initiates Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Announces Target Price $45
- UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $48 正面
- Goldman Sachs Initiates Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Announces Target Price $50
- Jefferies Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $40
- Evercore Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
- Scotiabank Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $40
- J.P. Morgan Sticks to Their Buy Rating for Teva (TEVA)
- J.P. Morgan Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
- BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $43 正面
- Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 A.m. ET
- Teva Pharmaceutical Industries(TEVA.US) Director Sells US$14.36 Million in Common Stock
- Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
- UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $42
- Piper Sandler Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $44
- Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $42 正面
暂无评论——快来第一个聊聊 TEVA。
登录后参与讨论。